logo
Share SHARE
FONT-SIZE Plus   Neg

CACI International Q2 Profit Rises; Lifts FY12 EPS Estimate - Quick Facts

CACI International Inc. (CACI) reported second-quarter net income attributable to the company of $41.1 million or $1.51 per share, compared to $33.2 million or $1.08 per share in the prior year quarter.

Pro forma adjusted net income attributable to the company for the quarter rose to $54.4 million or $2.00 per share from $45.9 million or $1.48 per share in the comparable quarter last year.

On average, 16 analysts polled by Thomson Reuters expected earnings of $1.30 per share for the quarter. Analysts' estimates typically exclude one-time items.

Revenues for the quarter grew 12.2 percent to $973.24 million from $867.28 million last year, while fifteen analysts estimated revenues of $952.78 million for the quarter.

Looking forward to the fiscal year 2012, the company raised its earnings guidance range to $5.72 - $5.94 per share, from the prior estimate of $5.55 - $5.80 per share. Analysts currently estimate earnings of $5.67 per share for the full year.

The company expects its revenue guidance for the full year 2012 to the range of $3,850 million to $4,050 million, same as the prior estimate. Analysts currently estimate revenues of $3.92 billion for the full year.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Automakers on Monday reported strong U.S. vehicle sales for the month of July, driven by continued demand for trucks and sport-utility vehicles amid an improving economy, lower gas prices and easy availability of credit. Detroit's Big Three - General Motors Co., Ford Motor Co. and FCA US, LLC - all reported vehicle sales above analyst expectations. British lender Lloyds Banking Group Plc. Friday reported higher profit in its first half, benefited by increased net interest income and margin as well as lower impairment. Looking ahead, the company lifted its net interest margin forecast. Amgen reported an increase in second-quarter profit, driven by sales of arthritis drug Enbrel and osteoporosis treatments Xgeva and Prolia, and improved margins. Both earnings and sales topped Wall Street estimates.
comments powered by Disqus
RELATED NEWS
Trade CACI now with 
Follow RTT